Eris Lifesciences Limited (NSE:ERIS)
India · Delayed Price · Currency is INR 1,425.70
-15.50 (-1.08%)
Feb 4, 2026, 2:10 PM IST
Eris Lifesciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 29,864 | 28,793 | 19,913 | 16,618 | 13,262 | 11,926 | |
Revenue Growth (YoY) | 20.16% | 44.59% | 19.83% | 25.31% | 11.20% | 12.71% |
Cost of Revenue | 7,534 | 7,332 | 3,964 | 3,613 | 2,640 | 2,419 |
Gross Profit | 22,330 | 21,461 | 15,950 | 13,005 | 10,621 | 9,507 |
Selling, General & Admin | 5,497 | 5,261 | 4,137 | 3,548 | 2,622 | 2,439 |
Other Operating Expenses | 6,148 | 6,018 | 5,038 | 4,070 | 3,108 | 2,762 |
Operating Expenses | 14,634 | 14,434 | 11,005 | 8,789 | 6,376 | 5,631 |
Operating Income | 7,696 | 7,027 | 4,945 | 4,217 | 4,245 | 3,876 |
Interest Expense | -2,097 | -2,313 | -848 | -261.68 | -41.46 | -18.02 |
Interest & Investment Income | 50.6 | 50.6 | 70.1 | 22.99 | 60.98 | 22.85 |
Earnings From Equity Investments | 12.3 | 0.6 | - | - | - | - |
Currency Exchange Gain (Loss) | 0.9 | 0.9 | 18.6 | - | - | - |
Other Non Operating Income (Expenses) | 85.2 | 92.1 | 55.7 | 17.22 | 15.19 | 14.46 |
EBT Excluding Unusual Items | 5,748 | 4,858 | 4,241 | 3,995 | 4,280 | 3,895 |
Gain (Loss) on Sale of Investments | 39.8 | 39.8 | 93.8 | 71.32 | 166.09 | 49.77 |
Gain (Loss) on Sale of Assets | -9.2 | -9.2 | -21.4 | -20.05 | -42.54 | -0.18 |
Other Unusual Items | 0.2 | 0.2 | - | - | 18.68 | - |
Pretax Income | 5,779 | 4,889 | 4,313 | 4,046 | 4,422 | 3,945 |
Income Tax Expense | 1,296 | 1,142 | 342.2 | 304.83 | 364.09 | 393.62 |
Earnings From Continuing Operations | 4,483 | 3,747 | 3,971 | 3,742 | 4,058 | 3,551 |
Minority Interest in Earnings | -332.2 | -228.3 | -50.7 | 79.98 | 3.24 | - |
Net Income | 4,151 | 3,518 | 3,921 | 3,822 | 4,061 | 3,551 |
Net Income to Common | 4,151 | 3,518 | 3,921 | 3,822 | 4,061 | 3,551 |
Net Income Growth | 19.11% | -10.26% | 2.59% | -5.90% | 14.36% | 19.78% |
Shares Outstanding (Basic) | 136 | 136 | 136 | 136 | 136 | 136 |
Shares Outstanding (Diluted) | 136 | 136 | 136 | 136 | 136 | 136 |
Shares Change (YoY) | 0.01% | 0.09% | - | 0.19% | 0.02% | -1.03% |
EPS (Basic) | 30.51 | 25.85 | 28.82 | 28.10 | 29.89 | 26.16 |
EPS (Diluted) | 30.46 | 25.81 | 28.79 | 28.07 | 29.88 | 26.14 |
EPS Growth | 19.06% | -10.35% | 2.56% | -6.06% | 14.31% | 21.07% |
Free Cash Flow | 6,044 | 9,100 | 3,569 | -5,497 | 2,572 | 3,496 |
Free Cash Flow Per Share | 44.36 | 66.77 | 26.21 | -40.37 | 18.93 | 25.73 |
Dividend Per Share | - | 7.350 | - | 7.350 | 6.010 | 5.500 |
Dividend Growth | - | - | - | 22.30% | 9.27% | 91.64% |
Gross Margin | 74.77% | 74.53% | 80.10% | 78.26% | 80.09% | 79.72% |
Operating Margin | 25.77% | 24.40% | 24.83% | 25.37% | 32.01% | 32.50% |
Profit Margin | 13.90% | 12.22% | 19.69% | 23.00% | 30.62% | 29.78% |
Free Cash Flow Margin | 20.24% | 31.61% | 17.92% | -33.08% | 19.40% | 29.31% |
EBITDA | 10,552 | 10,047 | 6,625 | 5,259 | 4,827 | 4,261 |
EBITDA Margin | 35.33% | 34.90% | 33.27% | 31.65% | 36.40% | 35.73% |
D&A For EBITDA | 2,856 | 3,021 | 1,681 | 1,043 | 582.18 | 384.9 |
EBIT | 7,696 | 7,027 | 4,945 | 4,217 | 4,245 | 3,876 |
EBIT Margin | 25.77% | 24.40% | 24.83% | 25.37% | 32.01% | 32.50% |
Effective Tax Rate | 22.43% | 23.36% | 7.93% | 7.53% | 8.23% | 9.98% |
Revenue as Reported | 30,158 | 29,120 | 20,330 | 16,963 | 13,731 | 12,206 |
Advertising Expenses | - | 180.6 | 66.8 | 63.85 | 87.47 | 125.05 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.